Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

US7902229B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Rolf Bohlmann · Berlin, DE
• Martin Haberey · Berlin, DE
• Andreas Huth · Berlin, DE
• Stuart Ince · Berlin, DE
• Martin Krueger · Berlin, DE
• Karl-Heinz Thierauch · Berlin, DE
• Holger Hess-Stumpp · Berlin, DE
• Andreas Reichel · Berlin, DE

Key dates

• Filing date: Nov 3, 2005
• Grant date: Mar 8, 2011
• Expiry date: Mar 31, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.